Incidence of natural resistance mutations in naïve chronic hepatitis B patients: A systematic review and meta-analysis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue 2, 2015, Pages 252-261

  Zhang, Qi ^a   Liao, Yun ^a   Cai, Bei ^a   Li, Yi ^a   Li, Lixin ^a   Zhang, Junlong ^a   An, Yunfei ^a   Wang, Lanlan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Antiviral drug resistance; Hepatitis B virus; Incidence; Mutation; Reverse transcriptase

Indexed keywords

HEPATITIS B ANTIGEN; ANTIVIRUS AGENT; LAMIVUDINE;

ARTICLE; EMBASE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS B VIRUS GENOTYPE C; HUMAN; MEDLINE; META ANALYSIS; MUTATION RATE; PRIORITY JOURNAL; SPONTANEOUS MUTATION; SYSTEMATIC REVIEW; ANTIVIRAL RESISTANCE; BIBLIOGRAPHIC DATABASE; CHINA; CROSS-SECTIONAL STUDY; DRUG EFFECTS; FEMALE; GENETICS; GENOTYPE; HEPATITIS B, CHRONIC; INCIDENCE; MALE; MUTATION; SEX DIFFERENCE; VIROLOGY;

ANTIVIRAL AGENTS; CHINA; CROSS-SECTIONAL STUDIES; DATABASES, BIBLIOGRAPHIC; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INCIDENCE; LAMIVUDINE; MALE; MUTATION; SEX FACTORS;

EID: 84921508742     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12831     Document Type: Article

References (50)

1. Trépo C, Chan HLY, Lok A. Hepatitis B virus infection. Lancet 2014; doi: 10.1016/S0140-6736(14)60220-8.
2. Chen DS. From hepatitis to hepatoma: lessons from type B viral hepatitis. Science 1993; 262: 369-370.
3. Di Bisceglie AM. Hepatitis B and hepatocellular carcinoma. Hepatology 2009; 49: S56-60.
4. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J. Hepatol. 2012; 57: 167-185.
5. Liaw YF, Kao JH, Piratvisuth T etal. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol. Int. 2012; 6: 531-561.
6. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
7. Sun J, Hou JL. Management of chronic hepatitis B: experience from China. J. Viral Hepat. 2010; 17 (Suppl. 1): 10-17.
8. Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance: mechanisms, detection and interpretation. J. Hepatol. 2006; 44: 593-606.
9. Lok AS, Zoulim F, Locarnini S etal. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007; 46: 254-265.
10. Locarnini S. Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol. Int. 2008; 2: 147-151.
11. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009; 137: 1593-1608.
12. Locarnini S, Zoulim F. Molecular genetics of HBV infection. Antivir. Ther. 2010; 15: 3-14.
13. Yuen LK, Locarnini SA. Genetic variability of hepatitis B virus and response to antiviral treatments: searching for a bigger picture. J. Hepatol. 2009; 50: 445-448.
14. Kobayashi S, Ide T, Sata M. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J. Hepatol. 2001; 34: 584-586.
15. Kirishima T, Okanoue T, Daimon Y etal. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J. Hepatol. 2002; 37: 259-265.
16. Akarsu M, Sengonul A, Tankurt E etal. YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay. J. Gastroenterol. Hepatol. 2006; 21: 1783-1788.
17. Jardi R, Rodriguez-Frias F, Schaper M etal. Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients. J. Viral Hepat. 2007; 14: 835-840.
18. Nguyen MH, Garcia RT, Trinh HN etal. Prevalence of hepatitis B virus DNA polymerase mutations in treatment-naive patients with chronic hepatitis B. Aliment. Pharmacol. Ther. 2009; 30: 1150-1158.
19. Girones R, Miller RH. Mutation rate of the hepadnavirus genome. Virology 1989; 170: 595-597.
20. Huang ZM, Huang QW, Qin YQ etal. YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines. World J. Gastroenterol. 2005; 11: 867-870.
21. Lee YS, Suh DJ, Lim YS etal. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006; 43: 1385-1391.
22. Snow-Lampart A, Chappell B, Curtis M etal. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 2011; 53: 763-773.
23. Mahabadi M, Norouzi M, Alavian SM etal. Drug-related mutational patterns in hepatitis B virus (HBV) reverse transcriptase proteins from Iranian treatment-naive chronic HBV patients. Hepat. Mon. 2013; 13: e6712.
24. Nishijima N, Marusawa H, Ueda Y etal. Dynamics of hepatitis B virus quasispecies in association with nucleos(t)ide analogue treatment determined by ultra-deep sequencing. PLoS ONE 2012; 7: e35052.
25. Tseng TC, Liu CJ, Wang CC etal. Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels. Antivir. Ther. 2009; 14: 203-210.
26. Liu BM, Li T, Xu J etal. Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naive Chinese patients. Antiviral Res. 2010; 85: 512-519.
27. Ismail AM, Samuel P, Eapen CE, Kannangai R, Abraham P. Antiviral resistance mutations and genotype-associated amino acid substitutions in treatment-naive hepatitis B virus-infected individuals from the Indian subcontinent. Intervirology 2012; 55: 36-44.
28. Tauseef I, Iqbal F, Rehman W, Ali M, Qureshi JA, Aslam MA. A PCR-RFLP based protocol for the detection of hepatitis B virus variants in some lamivudine-untreated chronic hepatitis B virus carriers in Pakistan. Pak. J. Pharm. Sci. 2012; 25: 349-352.
29. Tan YW, Ge GH, Zhao W etal. YMDD motif mutations in chronic hepatitis B antiviral treatment naive patients: a multi-center study. Braz. J. Infect. Dis. 2012; 16: 250-255.
30. Stroup DF, Berlin JA, Morton SC etal. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-2012.
31. Vutien P, Trinh HN, Garcia RT etal. Mutations in HBV DNA polymerase associated with nucleos(t)ide resistance are rare in treatment-naive patients. Clin. Gastroenterol. Hepatol. 2014; 12: 1363-1370.
32. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology 2009; 49: S45-55.
33. Tsubota A. How do naturally occurring YMDD-motif mutants influence the clinical course of lamivudine-naive patients with chronic hepatitis B virus infection? J. Gastroenterol. Hepatol. 2006; 21: 1769-1771.
34. Lai CL, Dienstag J, Schiff E etal. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. 2003; 36: 687-696.
35. Yao GB, Zhu M, Cui ZY, Wang BE, Yao JL, Zeng MD. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China. J. Dig. Dis. 2009; 10: 131-137.
36. Lo AO, Wong GL. Current developments in nucleoside/nucleotide analogues for hepatitis B. Expert Rev. Gastroenterol. Hepatol. 2014; 8: 607-622.
37. Marcellin P, Gane E, Buti M etal. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381: 468-475.
38. Heathcote EJ, Marcellin P, Buti M etal. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011; 140: 132-143.
39. Tenney DJ, Rose RE, Baldick CJ etal. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naivepatients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-1514.
40. Lai CL, Shouval D, Lok AS etal. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2006; 354: 1011-1020.
41. Tenney DJ, Levine SM, Rose RE etal. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob. Agents Chemother. 2004; 48: 3498-3507.
42. Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: recent advances. J. Gastroenterol. Hepatol. 2011; 26 (Suppl. 1): 123-130.
43. Sunbul M. Hepatitis B virus genotypes: global distribution and clinical importance. World J. Gastroenterol. 2014; 20: 5427-5434.
44. Liao Y, Hu X, Chen J etal. Precore mutation of hepatitis B virus may contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. PLoS ONE 2012; 7: e38394.
45. Wiegand J, Hasenclever D, Tillmann HL. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence. Antivir. Ther. 2008; 13: 211-220.
46. Liu Y, Wang C, Zhong Y etal. Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection. J. Viral Hepat. 2011; 18: e29-39.
47. Pan XP, Li LJ, Du WB, Li MW, Cao HC, Sheng JF. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C. J. Viral Hepat. 2007; 14: 767-774.
48. Damerow H, Yuen L, Wiegand J etal. Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern. J. Med. Virol. 2010; 82: 1850-1858.
49. Yang HI, Sherman M, Su J etal. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J. Clin. Oncol. 2010; 28: 2437-2444.
50. Tan Y, Ding K, Su J etal. The naturally occurring YMDD mutation among patients chronically infected HBV and untreated with lamivudine: a systematic review and meta-analysis. PLoS ONE 2012; 7: e32789.